Reuters logo
BRIEF-Savara reports positive interim results from a 50-patient open-label phase 2 study of aironite
July 11, 2017 / 12:14 PM / 2 months ago

BRIEF-Savara reports positive interim results from a 50-patient open-label phase 2 study of aironite

July 11 (Reuters) - Savara Inc:

* Savara Inc reports positive interim results from an ongoing 50-patient open-label phase 2 study of aironite in patients with pulmonary hypertension

* Says in 41 patients enrolled to date in study, administration of aironite significantly improved multiple hemodynamic measures

* Savara Inc - most pronounced improvements seen in patients with pulmonary hypertension due to heart failure with preserved ejection fraction

* Savara Inc - Aironite significantly lowered pulmonary artery pressures and significantly increased pulmonary arterial compliance

* Savara Inc - Aironite was generally well-tolerated and no significant safety concerns were identified, supporting primary safety outcome of study Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below